Accessibility Menu
CanSino Biologics logo

CanSino Biologics(SEHK) 6185

Market CapHK$7.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-7%
5 Year-90%
1 Year-40%
1 Month+27%
HK$29.54
+0.14%
+0.04Today
CanSino Biologics last closing stock price
MetricPriceDate
Last closeHKD 29.502026-08-31
CanSino Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.26%HKD 27.002026-08-24
1 month+26.72%HKD 23.282026-07-31
3 month+15.96%HKD 25.442026-06-02
Year to date-15.52%HKD 34.922025-12-31
1 year-39.62%HKD 48.862025-08-29
3 year+28.26%HKD 23.002023-08-31
5 year-90.33%HKD 305.002021-09-01
Since inception-7.28%HKD 34.262019-03-28

CanSino Biologics Financials at a Glance

Market Cap

HK$7.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.23B

Net Income (TTM)

CN¥40.63M

EPS (TTM)

HK$0.18

P/E Ratio

160.85

Dividend

HK$0.00

Beta (Volatility)

-0.01 (Low)

Price

HK$29.54

Volume

7,357,880

Open

HK$29.96

Previous Close

HK$29.50

Daily Range

HK$28.90 - HK$30.96

52-Week Range

HK$19.22 - HK$56.55

Estimated Earnings Date

Nov 2, 2026

6185 News

GettyImages-1220960132

Here's Your Guide to the Coronavirus Vaccine Leaders

Adria CiminoJul 26, 2020
GettyImages-1218961180

CanSino's COVID-19 Vaccine Was Just Approved for Limited Use in China. Here's What Investors Should Know.

Alex CarchidiJul 7, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CanSino Biologics

CanSino Biologics Inc. is a biotechnology company focused on the development, manufacturing, and commercialization of vaccines in China. The company is known for its innovative vaccine solutions, including those for COVID-19 and other infectious diseases.

Products and Services
  • Convidecia and Ad5-nCoV for Inhalation vaccines for COVID-19
  • Ad5-EBOV vaccine for Ebola virus
  • DTcP vaccine for infants and adolescents to prevent pertussis
Growth Outlook
  • Expansion into international markets is underway, enhancing global reach
  • Pipeline includes multiple vaccines in various clinical trial phases
  • Strong R&D investment supports future product development and innovation
Financial Highlights
  • Recent quarterly revenue of 188.6 million CNY, showing potential for growth
  • Trailing twelve months (TTM) gross profit margin at 75%, indicating strong profitability
  • Current ratio of 4.11 suggests robust liquidity position
CanSino Biologics Inc. has established itself as a key player in the biotechnology sector, particularly in vaccine development. The company's focus on innovative solutions positions it well for future growth, especially as global demand for vaccines continues to rise. With a strong pipeline of products and a commitment to research and development, CanSino is poised to capitalize on emerging opportunities in the healthcare market. The financial metrics indicate a solid foundation, with a significant gross profit margin and a favorable liquidity position, which may attract potential investors looking for growth in the biotechnology industry.
AI Generated • Aug 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,134

CEO

Xue Feng Yu, PhD

Website

www.cansinotech.com

Headquarters

Tianjin, TI 300457, CN

6185 Financials

Key Financial Metrics (TTM)

Gross Margin

72.43%

Operating Margin

1.02%

Net Income Margin

3.29%

Return on Equity

0.82%

Return on Capital

-1.81%

Return on Assets

0.59%

Earnings Yield

0.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$7.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.04M

Volume

7.36M

Avg. Volume

3.14M

Financials (TTM)

Gross Profit

CN¥879.35M

Operating Income

-CN¥56.71M

EBITDA

CN¥38.17M

Operating Cash Flow

CN¥40.25M

Capital Expenditure

-CN¥168.71M

Free Cash Flow

-CN¥128.37M

Cash & ST Invst.

CN¥1.84B

Total Debt

CN¥979.87M

CanSino Biologics Performance Analysis

CanSino Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 1,198,975,100-76.9%
20232023-12-31CNY 381,425,419-68.2%
20242024-12-31CNY 894,358,900134.5%
20252025-12-31CNY 1,148,936,46728.5%
CanSino Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3026.5%
Q42025-12-3119.2%
Q12026-03-31-49.0%
Q22026-06-3089.9%
CanSino Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -4.28N/A
20232023-12-31CNY -6.6455.1%
20242024-12-31CNY -1.66-74.9%
20252025-12-31CNY 0.12N/A
CanSino Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-301846.0%
Q42025-12-31-53.8%
Q12026-03-31-415.0%
Q22026-06-30200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥358.01M

+46.0%

Gross Profit

CN¥243.41M

+27.8%

Gross Margin

67.99%

N/A

Market Cap

HK$7.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$6.43M

N/A

Employees

1,134

N/A

Net Income

CN¥39.53M

+2137.9%

EBITDA

CN¥60.36M

+373.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.84B

-43.2%

Total Debt

CN¥979.87M

-48.1%

Accounts Receivable

CN¥965.29M

+46.2%

Inventory

CN¥387.67M

+14.1%

Long Term Debt

CN¥909.33M

+4.1%

Short Term Debt

CN¥70.54M

-93.1%

Return on Assets

0.59%

N/A

Return on Invested Capital

0.21%

N/A

Free Cash Flow

-CN¥32.89M

+21.6%

Operating Cash Flow

-CN¥5.98M

-123.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 6185

What is the current price of CanSino Biologics?

CanSino Biologics is trading at HK$29.54 per share.

What is the 52-week range for CanSino Biologics?

Over the past 52 weeks, CanSino Biologics has traded between HK$19.22 and HK$56.55.

How much debt does CanSino Biologics have?

As of the most recent reporting period, CanSino Biologics reported total debt of CN¥1.13B.

How much cash does CanSino Biologics have on hand?

CanSino Biologics reported CN¥1.36B in cash and cash equivalents in its most recent financial results.

What is CanSino Biologics’s dividend yield?

CanSino Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services